This bill enacts R.S. 22:1028.6, which mandates that all health coverage plans in Louisiana provide coverage for pediatric acute-onset neuropsychiatric syndrome (PANS), pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), and other types of autoimmune encephalitis (AE). The legislation emphasizes the importance of early treatment for these conditions to prevent severe neurological damage and mental health issues. It outlines that coverage may include various therapies, such as intravenous immunoglobulin therapy, and may be subject to standard deductibles and copayments.

Additionally, the bill allows insurers to consider, but not strictly adhere to, treatment recommendations from medical professional consortia when determining coverage for these disorders. It specifies that intravenous immunoglobulin treatments may be limited to three monthly courses unless further treatment is deemed medically necessary. The act will be known as "The Gillian Guiffreda Act" and will apply to new health coverage plans issued on or after January 1, 2026, with existing plans required to conform by their renewal date, but no later than January 1, 2027.